

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting
FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)
10903 New Hampshire Avenue, Silver Spring, Maryland
December 10, 2019

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Yinghua Wang, PharmD, MPH, RAC

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

John H. Alexander, MD, MHSc

Professor of Medicine
Department of Medicine, Division of Cardiology
Duke University School of Medicine
Durham, North Carolina

Jacqueline D. Alikhaani, BA

(Consumer Representative)
Volunteer and Advocate
American Heart Association
Los Angeles, California

Barry R. Davis, MD, PhD

Guy S. Parcel Chair in Public Health
Professor, Department of Biostatistics and Data
Science
Director, Coordinating Center for Clinical Trials
The University of Texas School of Public Health
Houston, Texas

C. Michael Gibson, MD, MS

Professor of Medicine
Harvard Medical School
President
Combined non-profit Baim and PERFUSE
Research Institutes
Boston, Massachusetts

Julia B. Lewis, MD

(Chairperson)
Professor of Medicine
Division of Nephrology
Vanderbilt Medical Center
Nashville, Tennessee

John M. Mandrola, MD, FACC

Electrophysiologist
Baptist Medical Associates
Louisville, Kentucky

David J. Moliterno, MD

Professor and Chairman
Department of Internal Medicine
University of Kentucky Medical Center
Lexington, Kentucky

Patrick H. Nachman, MD

Professor of Medicine
Director, Division of Renal Diseases and
Hypertension, Department of Medicine
University of Minnesota
Minneapolis, Minnesota

Milton Packer, MD

Distinguished Scholar in Cardiovascular Medicine
Baylor Heart and Vascular Institute
Baylor University Medical Center
Dallas, Texas

Paul M. Ridker, MD MPH, FACC, FAHA

Eugene Braunwald Professor of Medicine
Harvard Medical School
Director, Center for Cardiovascular Disease
Prevention, Division of Preventative Medicine
Brigham and Women's Hospital
Boston, Massachusetts

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Cardiovascular and Renal Drugs Advisory Committee (AAC) Meeting
December 10, 2019

DRAFT MEETING ROSTER (cont.)

CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

David G. Soergel, MD

(Industry Representative)

Global Head

Cardiovascular, Renal and Metabolism Development

Novartis Pharma

East Hanover, New Jersey

TEMPORARY MEMBERS (Voting)

James Floyd, MD, MS

Assistant Professor of Medicine and Epidemiology

Cardiovascular Health Research Unit

University of Washington

Seattle, Washington

Nedra Hazlett, MSN, CRNP

(Patient Representative)

Women's Health Nurse Practitioner

Administrator, Atrial Fibrillation Support Forum

Murrysville, Pennsylvania

Jenna M. Merandi, PharmD, MS, CPPS

Medication Safety Officer

Nationwide Children's Hospital

Columbus, Ohio

Matthew Needleman, MD, FACC, FHRS

Commander, Medical Corps, U.S. Navy

Program Director, Cardiovascular Diseases

Fellowship, National Capital Consortium

Director, Arrhythmia Services

Walter Reed National Military Medical Center

Associate Professor of Medicine and Pediatrics

Uniformed Services University of Health Sciences

Bethesda, Maryland

FDA PARTICIPANTS (Non-Voting)

Ellis F. Unger, MD

Director

Office of Drug Evaluation I (ODE I)

Office of New Drugs (OND), CDER, FDA

Norman Stockbridge, MD, PhD

Director

Division of Cardiovascular and Renal Products

(DCaRP), ODE I, OND, CDER, FDA